YY1: a key regulator inhibits gastric cancer ferroptosis and mediating apatinib-resistance

YY1: a key regulator inhibits gastric cancer ferroptosis and mediating apatinib-resistance

Abstract Objective Gastric cancer (GC) stands as a prevalent and deadly global malignancy. Despite its role as a preoperative neoadjuvant therapy, Apatinib’s effectiveness is curtailed among GC patients exhibiting elevated YY1 expression. YY1’s connection to adverse prognosis, drug resistance, and G...

Full description

Bibliographic Details
Main Authors:	Zi-Han Geng, Jun-Xian Du, Yue-Da Chen, Pei-Yao Fu, Ping-Hong Zhou, Wen-Zheng Qin, Yi-Hong Luo
Format:	Article
Language:	English
Published:	BMC 2024-02-01
Series:	Cancer Cell International
Subjects:	Gastric cancer YY1 Ferroptosis Apatinib p53
Online Access:	https://doi.org/10.1186/s12935-024-03262-z

Similar Items

Expression of p53 as a biomarker in determining response to apatinib for advanced gastric cancer
by: Zhiyuan Qiu, et al.
Published: (2023-08-01)

SIRT1 is transcriptionally repressed by YY1 and suppresses ferroptosis in rheumatoid arthritis
by: Yuwei Zhan, et al.
Published: (2023-03-01)

Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil
by: Xu Z, et al.
Published: (2019-05-01)

Effectiveness and safety of low‐dose apatinib in advanced gastric cancer: A real‐world study
by: Yingying Du, et al.
Published: (2020-07-01)

Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study
by: Ya-Ya Deng, et al.
Published: (2023-04-01)

Quercetin Induces Apoptosis in HepG2 Cells <i>via</i> Directly Interacting with YY1 to Disrupt YY1-p53 Interaction
by: Hui Guan, et al.
Published: (2023-02-01)

Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review
by: Dingyi Jiang, et al.
Published: (2020-07-01)

Long-term survival in metastatic gastric cancer patient with Apatinib plus S-1 maintenance treatment following first-line chemotherapy—case report
by: Zhen Wang, et al.
Published: (2024-11-01)

Efficacy and safety of apatinib in the second-line treatment of advanced gastric cancer
by: GUO Mengya, CHEN Yue, PENG Weiwei, SHA Huanhuan, FANG Ying, ZHOU Guoren
Published: (2025-01-01)

Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis
by: Binlong Chen, et al.
Published: (2024-05-01)

Analysis of the correlation between the dose exposure intensity and apatinib in advanced gastric cancer: a retrospective cohort study
by: Xiao Ma, et al.
Published: (2025-02-01)

Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis
by: Jincheng Wang, et al.
Published: (2024-05-01)

Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma
by: Yonggang Wang, et al.
Published: (2022-10-01)

Genome-wide CRISPR screen identifies ESPL1 limits the response of gastric cancer cells to apatinib
by: Bei Zhang, et al.
Published: (2024-02-01)

Integration of pharmacoproteomic and computational approaches reveals the cellular signal transduction pathways affected by apatinib in gastric cancer cell lines
by: Yosui Nojima, et al.
Published: (2023-01-01)

Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer
by: Guohu Han, et al.
Published: (2023-07-01)

Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer
by: Qingli Cui, et al.
Published: (2022-10-01)

Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review
by: Huifang Lv, et al.
Published: (2023-01-01)

SOX combined with apatinib and camrelizumab in the treatment of resectable locally advanced gastric cancer: a case report
by: JiKe Hu, et al.
Published: (2024-07-01)

SIRT1/APE1 promotes the viability of gastric cancer cells by inhibiting p53 to suppress ferroptosis
by: Zhao Huijin, et al.
Published: (2023-02-01)

A pH-Responsive Drug-Delivery System Based on Apatinib-Loaded Metal-Organic Frameworks for Ferroptosis-Targeted Synergistic Anti-Tumor Therapy
by: Yang F, et al.
Published: (2024-09-01)

Homeostasis Imbalance of YY2 and YY1 Promotes Tumor Growth by Manipulating Ferroptosis
by: Yanjun Li, et al.
Published: (2022-05-01)

Case report: Long-term partial response of apatinib plus paclitaxel as second-line therapy in a patient with metastatic gastric cancer
by: Shengya Fu, et al.
Published: (2022-08-01)

Complete remission of alpha-fetoprotein-producing gastric cancer by combined tislelizumab-apatinib treatment of a patient with proficient mismatch repair: a case report
by: Jinyu Xiang, et al.
Published: (2022-09-01)

Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
by: Le Zhang, et al.
Published: (2023-03-01)

Research on the Mechanism and Prevention of Hypertension Caused by Apatinib Through the RhoA/ROCK Signaling Pathway in a Mouse Model of Gastric Cancer
by: Wenjuan Wang, et al.
Published: (2022-06-01)

Corrigendum: Research on the mechanism and prevention of hypertension caused by apatinib through the RhoA/ROCK signaling pathway in a mouse model of gastric cancer
by: Wenjuan Wang, et al.
Published: (2022-10-01)

Postprandial secretion of insulin and peptide YY when taking erythritol and sucrose
by: N. V. Silina, et al.
Published: (2025-01-01)

Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma
by: Xie L, et al.
Published: (2020-01-01)

Microvascular rarefaction caused by the NOTCH signaling pathway is a key cause of TKI-apatinib-induced hypertension and cardiac damage
by: WenJuan Wang, et al.
Published: (2024-02-01)

Baicalin enhances the chemotherapy sensitivity of oxaliplatin-resistant gastric cancer cells by activating p53-mediated ferroptosis
by: Lihua Shao, et al.
Published: (2024-05-01)

YY1 Is a Key Player in Melanoma Immunotherapy/Targeted Treatment Resistance
by: Dominika Kwiatkowska, et al.
Published: (2022-06-01)

Apatinib monotherapy for early non-small cell lung cancer: a case report
by: Jiafang Xu, et al.
Published: (2024-10-01)

Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
by: Jinglei Qu, et al.
Published: (2023-04-01)

YY1-induced lncRNA XIST inhibits cartilage differentiation of BMSCs by binding with TAF15 to stabilizing FUT1 expression
by: Jian-Ying He, et al.
Published: (2022-06-01)

Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option
by: Hong-Hong Zhang, et al.
Published: (2022-08-01)

Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer‐bearing mice and patients
by: Mingtao Liu, et al.
Published: (2020-04-01)

Induction of ferroptosis by brucine suppresses gastric cancer progression through the p53-mediated SLCA711/ALOX12 axis
by: Jincheng Zhai, et al.
Published: (2024-07-01)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
by: Zhou Ling, et al.
Published: (2023-03-01)

Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
by: Lishu Yang, et al.
Published: (2018-05-01)